Effects of chronic morphine treatment on protein expression in rat dorsal root ganglia.
The initial aim of this study was to identify protein changes in the dorsal root ganglia (DRG) associated with long-term morphine treatment. We carried out a differential proteomics analysis on samples from the DRG of control and morphine-dependent rats (5-40 mg/kg, subcutaneously, twice daily for 28 days) after 4 days of morphine withdrawal. Proteins showing a statistically significant variation between the two groups were selected for identification by mass spectrometric analysis. Twelve proteins were unambiguously identified, with the majority being enzymes involved in energy metabolism and protein degradation, signaling and cytoskeletal proteins. Aldolase C and proteasome subunit alpha type 3 (PRC8 or alpha7) were further examined by Western blot analysis in the DRG, prefrontal cortex, nucleus accumbens, striatum, hippocampus, ventral tegmental area and locus coeruleus. In addition, expression of PRC8 in the nucleus accumbens tissue after spontaneous or naloxone-precipitated withdrawal was determined using immunohistochemical staining. Our results indicate that the expression levels of aldolase C and PRC8 proteins were altered in a time- and region-specific manner, and suggest that they could be implicated in the molecular changes underlying adaptations of neurons observed with chronic morphine treatment.
Li
Quan
Q
State Key Laboratory of Natural and Biomimetic Drugs, Peking University, Beijing, PR China.
Zhao
Xin
X
Zhong
Li-Jun
LJ
Yang
Hai-Yu
HY
Wang
Qi
Q
Pu
Xiao-Ping
XP
D000595:Amino Acid Sequence; D000818:Animals; D000911:Antibodies, Monoclonal / Q000378:metabolism*; D004305:Dose-Response Relationship, Drug; D005634:Fructose-Bisphosphate Aldolase / Q000737:chemistry / Q000378:metabolism*; D005727:Ganglia, Spinal / Q000378:metabolism*; D007150:Immunohistochemistry; D055104:Infusions, Subcutaneous; D007526:Isoelectric Point; D008297:Male; D008969:Molecular Sequence Data; D008970:Molecular Weight; D009020:Morphine / Q000008:administration & dosage / Q000037:antagonists & inhibitors / Q000494:pharmacology*; D009270:Naloxone / Q000494:pharmacology; D009292:Narcotic Antagonists / Q000494:pharmacology; D011897:Random Allocation; D051381:Rats; D017208:Rats, Wistar; D013375:Substance Withdrawal Syndrome / Q000378:metabolism; D013997:Time Factors
D000911:Antibodies, Monoclonal; D009292:Narcotic Antagonists; D009270:Naloxone; D009020:Morphine; D005634:Fructose-Bisphosphate Aldolase